PROF (Profound Medical) Short-Term Debt: $4.50 Mil (As of Mar. 2026)


PROF Profound Medical Corp PROF
73 GF Score
Price $7.18
GF Value $14.28
Valuation Possible Value Trap
! 1 Warning Sign
View Full Analysis

What is Profound Medical Short-Term Debt?

Profound Medical PROF -2.11% 73 Short-Term Debt is $4.50 Mil as of Mar. 2026. GuruFocus rates PROF with a GF Score™ of 73/100 and a GF Value™ of $14.28 (Possible Value Trap). The stock has 1 warning sign investors should review.

Profound Medical's Short-Term Debt for the quarter that ended in Mar. 2026 was $4.50 Mil.

Profound Medical's quarterly Short-Term Debt declined from Sep. 2025 ($4.48 Mil) to Dec. 2025 ($0.00 Mil) but then increased from Dec. 2025 ($0.00 Mil) to Mar. 2026 ($4.50 Mil).

Profound Medical's annual Short-Term Debt declined from Dec. 2023 ($2.10 Mil) to Dec. 2024 ($1.74 Mil) and declined from Dec. 2024 ($1.74 Mil) to Dec. 2025 ($0.00 Mil).

Profound Medical Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Profound Medical Short-Term Debt Related Terms

Profound Medical Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Profound Medical's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Profound Medical Short-Term Debt Chart

Profound Medical Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.52 2.10 1.74 0.00

Profound Medical Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 4.48 0.00 4.50
PROF
73GF Score
Profound Medical Corp PROF
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of $4.50 Mil mean?
Profound Medical (PROF) has a Short-Term Debt of $4.50 Mil as of Mar. 2026.
Is Profound Medical's Short-Term Debt too high?
Profound Medical's current Short-Term Debt is $4.50 Mil. Overall, Profound Medical has a GF Score™ of 73/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Profound Medical's Short-Term Debt compare to ABT and SYK?
Profound Medical's Short-Term Debt of $4.50 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Medical Devices & Instruments company?
A good Short-Term Debt depends on the Medical Devices & Instruments industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Profound Medical's current Short-Term Debt is $4.50 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Profound Medical stock overvalued right now?
Based on GuruFocus' analysis, Profound Medical (PROF) is currently considered Possible Value Trap. The stock's GF Value™ is $14.28, compared to a current price of $7.18 — trading 49.7% below its estimated fair value. The current Short-Term Debt is $4.50 Mil. Profound Medical's overall GF Score™ is 73/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Profound Medical (PROF), the current Short-Term Debt is $4.50 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Profound Medical (PROF) Overvalued in 2026?

Based on GuruFocus' analysis, Profound Medical stock appears to be undervalued. The current stock price of $7.18 is trading 49.7% below its estimated GF Value™ of $14.28. GuruFocus considers Profound Medical to be Possible Value Trap.

Key valuation signals for PROF:

  • Short-Term Debt: $4.50 Mil
  • GF Value™: $14.28 vs. price of $7.18 (49.7% below fair value)
  • GF Score™: 73/100 with 1 warning sign

No single metric tells the full story. See the PROF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Profound Medical Business Description

Other Exchanges PRN:Canada
Address 2400 Skymark Avenue, Unit 6, Mississauga, ON, CAN, L4W 5K5
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.
73GF Score

Get the complete analysis for PROF

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.18
Price
$14.28
GF Value